Table 2.
Reclassification | HPV status, n (%) | ||||||
---|---|---|---|---|---|---|---|
Total | Negative | Type 16 | Type 18/45 | Types 16 and 18/45 | Other | Unknown* | |
NILM | 36 (34.6) | 34 (94.4) | 0 (0) | 1 (2.8) | 0 (0) | 0 (0) | 1 (2.8) |
ASC-US | 62 (59.6) | 49 (79) | 3 (4.8) | 0 (0) | 6 (9.7) | 4 (6.5) | 0 (0) |
AGC | 2 (1.9) | 2 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
ASC-US and AGC | 2 (1.9) | 2 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
LSIL | 2 (1.9) | 0 (0) | 1 (50) | 0 (0) | 0 (0) | 1 (50) | 0 (0) |
HSIL | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Total | 104 (100) | 87 (83.7) | 4 (3.8) | 1 (1) | 6 (5.8) | 5 (4.8) | 1 (1) |
HPV = human papillomavirus; NILM = negative for intraepithelial lesions or malignancy; ASC-US = atypical squamous cells of undetermined significance; AGC = atypical glandular cells; LSIL = low-grade squamous intraepithelial lesions; HSIL = high-grade squamous intraepithelial lesions.
Testing not performed.